Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center

Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center

Background: Poor-risk advanced Renal cell carcinoma (RCC) are an under-evaluated and difficult to treat subset of patients with poor prognosis. While Temsirolimus is the approved first line therapy for this category, Tyrosine kinase inhibitors (TKIs) are also commonly uses as initial treatment. We p...

Full description

Saved in:
Bibliographic Details
Main Authors: Anant Ramaswamy, Amit Joshi, Vanita Noronha, Vijay Patil, Arvind Sahu, Deepan R Manickam, Rushabh Kothari, Nilesh Sable, Archi Agrawal, Santosh Menon, Kumar Prabhash
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2017-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Heng criteria
metastatic renal cell carcinoma
poor risk
tyrosine kinase inhibitor
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2017;volume=38;issue=3;spage=311;epage=315;aulast=Ramaswamy
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items